Table 1. Main Features of the Studies Included in the Meta-analysis.
| Source | Design | Study Population | Anticoagulant Dosages | Follow-up, mo | ||
|---|---|---|---|---|---|---|
| Overall | DOAC Group | Control Group | ||||
| APPRAISE | RCT (phase II) | 1715 | 1104 | 611 | Apixaban, 2.5 mg BID, 10 mg QD | 6 |
| APPRAISE 2 | RCT (phase III) | 7392 | 3705 | 3687 | Apixaban, 5 mg BID | 8 |
| APPRAISE J | RCT (phase II) | 150 | 99 | 51 | Apixaban, 2.5 mg BID, 10 mg QD | 6 |
| ATLAS ACS TIMI 46 | RCT (phase II) | 3491 | 2331 | 1160 | Rivaroxaban, 5, 10, 15, and 20 mg QD | 6 |
| ATLAS ACS 2 TIMI 51 | RCT (phase III) | 15 526 | 10 350 | 5176 | Rivaroxaban, 2.5 and 5 mg BID | 13 |
| REDEEM | RCT (phase II) | 1861 | 1490 | 371 | Dabigatran, 50, 75, and 110, 150 mg BID | 6 |
Abbreviations: APPRAISE, Apixaban for Prevention of Acute Ischemic Events; ATLAS ACS TIMI 46, Rivaroxaban versus Placebo in Patients With Acute Coronary Syndromes; BID, twice daily; DOAC, direct oral anticoagulant; QD, once daily; RCT, randomized clinical trial; REDEEM, Dose Finding Study for Dabigatran Etexilate in Patients With Acute Coronary Syndrome.